ABT · Healthcare

ABBOTT LABORATORIES

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-08

• Regulatory Approval MilestonesImportance 41 · Surprise 60
  Abbott received FDA approval for its Amplatzer Paraclose PVL Occluder, a device for structural heart procedures. The report also cites positive trial results for other cardiology and oncology devices but does not name…

News · 2026-11-07

• Regulatory Approval MilestonesImportance 59 · Surprise 60
  Third-party reporting says Abbott received FDA approval for the Amplatzer Paraclose PVL Occluder in late October or early November 2026. The article provides no financial impact, compliance cost, or revenue estimate…
• Product Launch and TransitionImportance 58 · Surprise 42
  Abbott received FDA approval for the Amplatzer Paraclose PVL Occluder in late October or early November 2026. The company reported strong study results for the investigational Amulet 360 and SonicForce coronary…

News · 2026-11-06

• Biohacking Wearables Market GrowthImportance 20 · Surprise 22
  A third-party market report identifies Abbott, alongside Apple, Samsung, Huawei, and Oura, among companies profiled in the biohacking wearable and consumer longevity device market. The report says the global market is…

News · 2026-11-05

• Licensing / Collaboration DealsImportance 31 · Surprise 42
  Abbott and Novo expanded their strategic collaboration on November 5, 2026, to launch Plosbrio (semaglutide) in Singapore and other Asia Pacific countries. Plosbrio is described as a second brand of Novo’s Ozempic for…
• Product Launch and TransitionImportance 31 · Surprise 42
  Abbott and Novo expanded their collaboration to launch Plosbrio® (semaglutide) in Singapore and other Asia Pacific countries. Plosbrio is a second brand of Ozempic® intended to broaden access to advanced type 2…

10-Q · 2026-11-04

• Liquidity and Cash PositionImportance 91 · Surprise 88
  At September 30, 2026, cash and cash equivalents were $4.052 billion, down from $8.522 billion at December 31, 2025. Long-term debt was $29.451 billion and current debt was $1.708 billion, compared with $9.896 billion…
• Interest Expense IncreaseImportance 76 · Surprise 82
  Net interest expense increased $253 million to $297 million in the third quarter of 2026. For the first nine months, it increased $521 million to $664 million. The increases primarily reflected interest on debt…
• Exact Sciences AcquisitionImportance 71 · Surprise 60
  Abbott completed its acquisition of Exact Sciences on March 23, 2026, for approximately $20.6 billion, paying $105 per common share in cash. Abbott funded the purchase primarily with $20.0 billion of long-term debt…
• Revenue Performance and MixImportance 64 · Surprise 56
  Third-quarter 2026 net sales rose 14.5% year over year to $13.013 billion, or 14.8% excluding foreign exchange; nine-month sales rose 11.9% to $36.770 billion, or 10.5% excluding foreign exchange. In the first nine…
• Operating Income and MarginsImportance 58 · Surprise 56
  Third-quarter operating earnings fell 34% to $1.358 billion from $2.057 billion, while nine-month operating earnings declined 24% to $4.396 billion from $5.802 billion. Third-quarter net sales grew 14% to $13.013…
• Operating Expense TrendsImportance 58 · Surprise 56
  Third-quarter research and development expense rose 17% to $2.579 billion from $2.207 billion. Third-quarter selling, general, and administrative expense increased 40% to $4.266 billion from $3.051 billion. For the…
• Operating Cash Flow and CapexImportance 48 · Surprise 40
  Net cash from operating activities totaled $5.5 billion in the first nine months of 2026, approximately $700 million below the prior-year period. The decline primarily reflected legal-settlement payments, higher…
• Geographic Market CommentaryImportance 48 · Surprise 40
  For the first nine months of 2026, total U.S. sales increased 17.7%, while total international sales increased 5.9% excluding foreign exchange. In Core Laboratory, diagnostic test sales on the Alinity platform…
• DOJ Infant Formula InvestigationImportance 47 · Surprise 60
  Abbott resolved investigations by the U.S. Department of Justice and complaints in September 2026 concerning its U.S. manufacturing of powdered infant formula. The DOJ and several states had partially intervened in a…
• Research and Development InvestmentImportance 47 · Surprise 48
  R&D expense increased $154 million, or 20.1%, to $920 million in the third quarter of 2026. For the first nine months, R&D expense rose $372 million, or 16.9%, to $2.6 billion. The increases primarily reflected the…
• Income Tax Rate ChangesImportance 42 · Surprise 40
  First-nine-month 2026 taxes on earnings included approximately $540 million of expense related to a deferred tax asset recognized as a significant non-cash tax benefit in a prior year, compared with approximately $460…
• Strategic Business SeparationImportance 41 · Surprise 60
  In October 2026, Abbott announced plans to separate its Nutrition business into an independent, publicly traded company that would include the Nutritional Products segment and brands such as Similac, PediaSure,…
• Infant Formula LitigationImportance 40 · Surprise 42
  Abbott faces lawsuits alleging that cow’s-milk-containing preterm infant formula and human milk fortifier caused necrotizing enterocolitis (NEC) and failed to warn of the risk. In September 2026, Abbott reached…
• Order Backlog and Book-to-BillImportance 38 · Surprise 24
  As of September 30, 2026, Abbott reported approximately $6.2 billion of estimated future revenue from unsatisfied or partially unsatisfied performance obligations in its Diagnostic Products segment. These obligations…
• EP and Rhythm Management GrowthImportance 36 · Surprise 40
  For the first nine months of 2026, Electrophysiology sales increased 13.8% excluding foreign exchange, primarily reflecting increased sales of ablation catheters and related portfolio products. Rhythm Management sales…
• Gross Margin DriversImportance 31 · Surprise 32
  Gross profit margin was 50.3% in the third quarter and 51.7% in the first nine months of 2026, versus 51.7% and 52.4%, respectively, in 2025. The decline primarily reflected higher intangible amortization following the…
• Product Launch and TransitionImportance 31 · Surprise 42
  Abbott received several significant product approvals and launched new products in 2026. Libre Duo, a dual glucose-ketone biowearable sensor, received CE Mark and FDA approval, while the Amulet 360 left atrial…
• Emerging Market Pharmaceutical GrowthImportance 30 · Surprise 40
  Established Pharmaceutical Products sales in Key Emerging Markets increased 10.4% excluding foreign exchange in the first nine months of 2026. Growth was led by double-digit increases in several countries across Latin…
• Capital Return ProgramImportance 24 · Surprise 14
  Abbott paid $3.294 billion of dividends in the first nine months of 2026, compared with $3.086 billion in the same period of 2025. Dividends declared for the nine-month period were $1.89 per common share, up from $1.77…
• Malaysian Tax Assessment AppealImportance 20 · Surprise 24
  In July 2024, Abbott received a tax assessment from Malaysian tax authorities for the 2023 tax year, applying a property capital gains tax to the value of shares associated with an intercompany affiliate sale. The…
• OECD Global Minimum TaxImportance 17 · Surprise 24
  The OECD’s Pillar 1 proposal would reallocate taxing rights among jurisdictions where in-scope multinationals operate, while Pillar 2 would impose a 15% minimum tax on earnings country by country. Numerous countries…
• IRS Tax DisputesImportance 13 · Surprise 6
  Abbott is contesting IRS notices of deficiency for the 2017–2020 U.S. federal tax years, primarily concerning proposed reallocations of income between U.S. entities and foreign affiliates. Abbott petitioned the U.S.…

News · 2026-11-04

• Amulet 360 Product DevelopmentImportance 34 · Surprise 42
  Abbott’s Amulet 360 left atrial appendage closure device achieved complete closure in 96.3% of patients with nonvalvular atrial fibrillation at one year in the pivotal VERITAS study. The study reported a 1.8% rate of…
• SonicForce Product DevelopmentImportance 17 · Surprise 24
  Abbott’s SonicForce Coronary IVL System was featured in TECTONIC trial data reported alongside the VERITAS results. The reporting described the system’s performance as strong in treating severe coronary artery…

News · 2026-11-03

• IVL Market and Product LaunchImportance 34 · Surprise 42
  Abbott reported that its investigational SonicForce coronary intravascular lithotripsy (IVL) system met the primary safety and effectiveness endpoints in the TECTONIC CAD IVL IDE study. The 30-day results showed low…

News · 2026-11-02

• Cephea Product Pipeline ProgressImportance 34 · Surprise 42
  Abbott initiated a pivotal clinical trial of its investigational Cephea mitral valve system, designed to replace diseased mitral valves and restore normal blood flow. Unlike Abbott’s Tendyne system, Cephea is delivered…
• SonicForce Product DevelopmentImportance 26 · Surprise 24
  Abbott’s investigational SonicForce Coronary Intravascular Lithotripsy System met safety and effectiveness goals in the TECTONIC study, with a 97% procedural success rate. The results add clinical evidence for Abbott’s…
• Amulet 360 Product DevelopmentImportance 26 · Surprise 24
  Abbott’s investigational Amulet 360 Left Atrial Appendage Occluder showed 96.3% complete closure with zero-millimeter leak in the pivotal VERITAS study. More than 98% of study patients remained free of stroke of the…
• CGM Coverage and PricingImportance 26 · Surprise 24
  Abbott and Dexcom are responding to insurance-coverage and pricing changes as Medicare plans to expand continuous glucose monitor coverage to Type 2 diabetes patients who do not use insulin. Abbott anticipates a…
• Healthcare Coverage PolicyImportance 26 · Surprise 24
  Medicare plans to expand continuous glucose monitor coverage to Type 2 diabetes patients who are not on insulin, with a CMS decision expected soon, according to the report. Abbott anticipates a slowdown and pricing…
• Regulatory RiskImportance 17 · Surprise 24
  The FDA has proposed changes to U.S. baby formula regulations intended to prevent future shortages and improve safety. The reported changes could require additional costs or operational adjustments for the independent…
• Product Liability LawsuitImportance 17 · Surprise 24
  A Texas man filed a product liability lawsuit alleging Abbott sales representatives repeatedly tried to reprogram his malfunctioning Proclaim Spinal Cord Stimulator rather than enabling proper medical treatment. The…
• ID NOW Distribution ExpansionImportance 11 · Surprise 24
  HSS Medical Supply entered a new vendor agreement with Abbott and added Abbott’s ID NOW rapid molecular testing platform to its catalog of more than 2,000 products. ID NOW is an instrument-based, CLIA-waived…

News · 2026-10-31

• Strategic Business SeparationImportance 34 · Surprise 42
  Abbott plans to separate its Nutrition business into a standalone public company. The reported rationale is to shift Abbott’s focus further toward medical technology and diagnostics. The article says the separation…

News · 2026-10-30

• Strategic Business SeparationImportance 40 · Surprise 42
  Third-party reporting says Abbott plans to separate its Nutrition business into a standalone company. The report provides no transaction terms, expected completion date, or financial impact. It also does not specify a…
• Diagnostic Market DemandImportance 30 · Surprise 40
  The report projects the global point-of-care INR testing market to grow from $1.58 billion in 2025 to $1.75 billion in 2026, a 10.4% CAGR. It attributes growth to cardiovascular disease prevalence, anticoagulant use,…
• CGM Competition and PricingImportance 17 · Surprise 24
  Dexcom, a competitor to Abbott in diabetes wearables, exceeded expectations for the September quarter and raised its guidance. The report’s headline characterizes the U.S. wearables market as taking off, indicating…

News · 2026-10-22

• Strategic Business SeparationImportance 71 · Surprise 60
  Abbott plans to separate its global Nutrition business into an independent publicly traded company with approximately $8.5 billion in annual sales. The transaction is expected to be completed by the end of 2027 and…
• Guidance / OutlookImportance 47 · Surprise 60
  Abbott reduced its 2026 guidance during its third-quarter earnings update. RBC attributed the guidance cuts to headwinds in Abbott’s diabetes and electrophysiology portfolios. Management also highlighted competitive…
• Nutrition Market DemandImportance 44 · Surprise 24
  Abbott’s global Nutrition business reported stronger third-quarter demand, driven by pediatric and adult nutrition sales. The portfolio includes Similac, Ensure and PediaSure, serving infant, pediatric and adult…
• Regulatory RiskImportance 44 · Surprise 60
  India's Food Safety and Standards Authority issued Abbott a notice concerning an allegedly noncompliant promotional video for Similac Advance 1. The notice involved an influencer's social-media promotion, which Abbott…
• Revenue Performance and MixImportance 36 · Surprise 14
  Abbott reported approximately 7% comparable sales growth in the third quarter of 2026. Adjusted earnings per share was $1.42, matching the level management had indicated. Third-quarter Nutrition sales benefited from…
• Competition and Market PositionImportance 17 · Surprise 24
  A 172-patient peer-reviewed study compared Catheter Precision’s LockeT suture-retention device with Abbott’s Perclose internal vascular closure device after large-bore venous access. The study covered…

Earnings call · 2026-10-21

• FX / Currency HeadwindsImportance 30 · Surprise 14
  Foreign exchange reduced third-quarter sales growth by 0.4% year over year, a slightly smaller headwind than Abbott expected in July. Based on current exchange rates, management expects FX to reduce fourth-quarter…
• CRC Screening Market DemandImportance 30 · Surprise 40
  Cologuard grew at a mid-teens rate, with growth in new users, rescreening, international markets, and care-gap programs. Management said care-gap program growth is valuable to health systems and insurers because it…
• Capital Return ProgramImportance 26 · Surprise 24
  Management said Abbott expects to grow its dividend next year and will have an opportunity for share buybacks. The company expects to make its last large tranche of debt paydown related to the St. Jude and Alere…
• LAA Closure CompetitionImportance 26 · Surprise 24
  Management said the left atrial appendage closure market remains challenging, with Abbott beginning to feel pressure one or two quarters after the market leader. It sees continued market growth and patient and…
• CGM Market DemandImportance 26 · Surprise 24
  Management said clinical data supports continuous glucose monitoring for people with type 2 diabetes who do not use insulin, describing CGMs as tools that provide information to help change behavior. Abbott is…
• Operating Margin DriversImportance 24 · Surprise 14
  Adjusted gross margin was 57.2% of sales in the third quarter, up 140 basis points year over year. Management attributed the improvement to favorable mix in the legacy Abbott portfolio and the addition of Exact…
• Nutrition Market DemandImportance 24 · Surprise 14
  Nutrition sales grew 5%, with growth across U.S. pediatric, international pediatric, U.S. adult, and international adult categories. Pediatric nutrition grew 9% worldwide and 11% in the U.S.; WIC contract wins helped…
• International Market GrowthImportance 23 · Surprise 24
  Management said Abbott has selected international markets in which to expand its acquired cancer-screening technology, choosing markets it believes can have the greatest impact rather than the markets typically…
• Healthcare Coverage PolicyImportance 20 · Surprise 24
  Abbott said it is not forecasting when CMS reimbursement may begin for continuous glucose monitoring (CGM) use by non-insulin-using type 2 diabetes patients, and is not factoring that reimbursement into its next-year…
• Regulatory RiskImportance 20 · Surprise 24
  Abbott said Cologuard Plus is a new test and that CMS reimbursement is being set through a process different from those for established tests, National Coverage Determinations, and some MedTech processes. The company…
• Cancer Testing Pricing and AdoptionImportance 17 · Surprise 24
  Management said blood-based cancer tests are currently priced at levels that limit broad uptake, even if they can produce strong growth rates from a small market base. It argued that much broader adoption would be…